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Abstract
Chronic renal failure is an important health care problem throughout the world, with an incidence of 337, 90, 107 
and 95 new cases per million inhabitants/year in the United States, Australia, New Zealand and the United Kingdom, 
respectively. These figures moreover invariably tend to increase. During the progression of renal damage, clinical 
manifestations are noted in practically all body organs and systems, and 90% of all affected patients experience oral 
symptoms. The existing management options range from simple measures based on changes in diet and life style, to 
different forms of dialysis (hemodialysis and peritoneal dialysis), and also kidney transplantation. Given the multiple 
oral manifestations of chronic renal failure, and the different repercussions of its treatment upon the oral cavity, 
these patients require special considerations and precautions in the face of dental treatment. Consultation with the 
nephrologist is essential before any dental treatment is carried out, in order to determine the condition of the patient, 
define the best moment for dental treatment, introduce the necessary pharmacological adjustments, or to establish 
other important aspects for preventing complications in the dental clinic.
The present study reviews the characteristics of the disease, the existing therapeutic options, and the considerations 
of relevance for the dental professional.
Key words: Chronic renal failure, glomerular filtration rate, dialysis, renal transplant, immunosuppressive therapy, renal 
osteodystrophy, oral lesions, gingival hyperplasia, dental management.
Indexed in: 
-Index Medicus / MEDLINE  /  PubMed            
-EMBASE, Excerpta Medica
-SCOPUS
-Indice Médico Español                                                        
-IBECS
              Article Number: 111111156
              © Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946 
              eMail:  medicina@medicinaoral.com 
Introduction
Each human kidney is composed of  about one million 
anatomical and functional units called nephrons. In 
turn, each nephron is composed of  a glomerule and 
tubule. The glomerule consists of  an interconnected 
network of  capillaries contained within a cup-like sac 
known as Bowman’s capsule, which continues with the 
proximal convoluted tubule. The latter in turn gives rise 
to different sequential segments: the loop of  Henle, the 
distal convoluted tubule, and the collector ducts. The 
final segment collects the urine from a number of  distal 
convoluted tubules and drains it directly into the renal 
papilla (1).
The kidneys have a number of important functions: (a) 
Excretion of  metabolic waste products. (b) Electrolyte 
regulation through the control of sodium, potassium and 
water excretion, and acid-base homeostasis. (c) Endocrine 
regulatory functions: eicosanoids (prostaglandins, throm-
boxanes, leukotrienes, prostacyclins, etc.), erythropoietin 
(EPO), the renin-angiotensin system, and vitamin D me-
tabolism (2). In particular, the renin-angiotensin system 
comprises one of the mechanisms involved in the control 
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of  blood pressure (BP): when the latter decreases, the 
kidney releases renin, which in turn triggers an enzymatic 
cascade that produces abundant blood angiotensin II – a 
hormone that increases global peripheral vascular resis-
tance and thus increases BP (3).
Classification of renal failure
When a nephron is destroyed it is unable to regenerate, and 
the kidneys compensate the loss through hypertrophy of 
the remaining nephrons, so that normal kidney function 
can be maintained until approximately half  of  all the 
existing nephrons have been destroyed. Once this point has 
been reached, symptoms of renal functional impairment 
begin to appear:
- Acute renal failure (ARF) is characterized by a sudden 
and important reduction in glomerular filtration rate 
(GFR) lasting for hours or days. The underlying causes 
are classified as pre-renal, intrinsically renal or post-renal 
(Table 1). In general, renal function is restored once the 
underlying cause has been resolved (4,5), and it is not 
common for the dental professional to treat a patient 
with ARF.
- Chronic renal failure (CRF) is characterized by a gradual 
reduction in the number of functional nephrons. There 
are many possible causes (Table 1) (5), and the natural 
course of CRF leads to terminal or end-stage renal failure 
(ESRF)(1,4).
- In ESRF, renal function has deteriorated to the point 
where the body suffers chronic systemic abnormalities. In 
this situation renal replacement therapy is required in the 
form of dialysis and/or kidney transplantation (1,2,4).
Chronic renal failure
CRF is defined on the basis of a glomerular filtration rate 
(GFR) of less than 60 ml/min/1.73 m2, or by the evidence 
of renal damage (micro- or macroalbuminuria, persistent 
hematuria, radiological anomalies) during a period of 
more than three months (5,6). 
As a result of the progressive renal damage, the excretion 
of body metabolic waste products is impaired, resulting in 
a state of intoxication called uremia, which is characterized 
by increased levels of acute phase proteins, certain cyto-
kines, and even macrophages. The endocrine functions of 
the kidney (secretion of vitamin D and erythropoietin) are 
also affected. CRF represents an extra-renal multiorgan 
disease state affecting the skeleton, lungs, gastrointestinal 
tract, heart and blood vessels, central and peripheral ner-
vous systems, and endocrine and reproductive functions 
(7,8).
Epidemiological data are available in different countries, 
and although the reported incidences differ from one 
region to another (337, 90, 107 and 95 new cases per mi-
llion inhabitants/year in the United States, Australia, New 
Zealand and the United Kingdom, respectively), CRF is 
a major health care problem throughout the world. The 
incidence increases with age; men are more often affected 
than women; and there are also ethnic differences (e.g., 
in the United States, Caucasians and Afro-Americans 
show a higher incidence of CRF than Asians or Native 
Americans)(9). In Spain, the reported prevalence of grade 
IV disease (severely diminished GFR: 30-59 ml/min/1.73 
m²) is 0.7-1.5% of the population, while grade III CRF 
(moderately diminished GFR: 15-29 ml/min/1.73 m²) 
affects 3.3-8.5% of the population (10).
The most frequent causes of CRF are diabetes mellitus, 
present in 40-60% of all patients with CRF that progress 
to ESRF (5,8); arterial hypertension, which affects 15-
30%; and glomerulonephritis, which is seen in less than 
10% of all cases. Only 2-3% of all CRF patients present 
renal polycystosis (5).
Following initial parenchymal damage, renal impairment 
gradually intensifies – ESRF being the end condition of 
the disease process. The causes of such progression are 
not fully clear, but may include: hyperfunction of  the 
remaining functional nephrons, systemic and intra-renal 
hypertension, the progression of immune damage, protei-
nuria, and protein and fat dietary loading (7).
Acute renal failure
Pre-renal
Gastrointestinal losses
Excessive perspiration
Bleeding
Burns with fluid sequestration
Renal losses
Cardiovascular failure
Liver failure
Intrinsic renal causes
Acute tubular necrosis (vasomotor nephropathy)
Severe cortical necrosis
Severe acute glomerulonephritis
Vasculitis
Malignant hypertension
Accelerated scleroderma
Allergic interstitial nephritis
Post-renal
Bilateral ureteral obstruction or ureteral obstruction in 
patients with a single kidney
Bladder obstruction
Bladder rupture
Urethral obstruction
Chronic renal failure
Chronic immune glomerulopathy
Hypertensive nephrosclerosis
Chronic tubulointerstitial diseases
Metabolic diseases (e.g., diabetes mellitus)
Congenital and hereditary renal processes (e.g., renal 
polycystic disease)
Table 1. Causes of renal failure.
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Diagnosis. The glomerular filtration rate is the best pa-
rameter for assessing renal function. The standard for 
measuring GFR is inulin clearance, though in practice this 
is not the most widely used method. Creatinine clearance 
overestimates GFR, and precise collection of the 24-hour 
urine samples needed to calculate such clearance is not 
easy (6,11). As a result, in recent years effort has centered 
on the development of formulas capable of determining 
GFR as exactly as possible, based on a simple plasma 
sample used to determine serum creatinine concentration 
(11). These formulas take into account patient age (GFR 
undergoes a physiological decline with age), sex (120 ml/
min/1.73 m2 is considered normal in males, versus 100 ml/
min/1.73 m2 in females) and race (5). Table 2 provides an 
estimate of equivalent GFR according to plasma creati-
nine and the clinical situation of the patient.
When evaluating the risk of progression of CRF and of 
the possible development of ESRF, it is necessary to detect 
and quantify proteinuria. In addition, in the early stages 
of CRF, normal or only slightly reduced GFR values may 
be observed despite an already manifest increase in protein 
excretion in urine. The latter is therefore more useful as 
an early marker of CRF (12). Albumin, the protein pre-
dominantly excreted by the kidneys in different types of 
disease, is easily detectable by means of a reactive strip 
test, or by means of other more precise techniques (11). 
Under some conditions, immunoglobulins can also be 
excreted in urine.
Clinical manifestations
a) General. The clinical signs and symptoms are related 
to the type of underlying renal or systemic problem, and 
to the rate of impairment of renal functional.
Uremic patients show generalized paleness as a result of 
anemia (7,9), brown hyperpigmentation of the nails and 
skin due to the retention of dietary pigments, and skin 
excoriations or scratches produced by intense generalized 
itching secondary to the accumulation of calcium and 
phosphate microcrystals (9). 
Arterial hypertension is the most common complication, 
and is attributed to the retention of sodium and water, 
and to activation of  the renin-angiotensin-aldosterone 
system (7,9,13).
These patients also suffer dyspnea (9) and gastrointestinal 
alterations such as anorexia, nausea and vomiting associa-
ted to the uremia (7,9), as well as an increased incidence 
of gastrointestinal bleeding episodes (13).
A frequent observation is anemia secondary to deficient 
erythropoiesis (1,7,13), and hemostasia is altered as a 
result of platelet dysfunction (7,13,14) and of the anti-
coagulants used in dialysis. The mechanical trauma to 
which the platelets are exposed during dialysis can reduce 
their counts. In addition, diminished platelet adhesion is 
observed, together with an increase in prostacyclin acti-
vity, lesser availability of platelet factor 3, and increased 
capillary fragility. All these factors can lead to an increased 
risk of bleeding problems (2).
The decrease in cellular immune function and the che-
motactic defects induced by uremia predispose patients 
to infection, which represents the second most important 
cause of death in such individuals (8).
The alterations in mineral metabolism in turn lead to renal 
osteodystrophy, which manifests in the form of skeletal 
defects, fractures, pain, and joint and periarticular calci-
fications (7).
Involvement of the central nervous system is expressed in 
the form of restlessness, apathy and insomnia (9).
The endocrine-metabolic alterations can manifest as 
hypoparathyroidism (9), retarded growth (7,9), diminis-
hed libido, erectile dysfunction in males, and infertility 
in women (9).
b) Oral. A full 90% of all patients with CRF suffer oral 
signs and symptoms (2) affecting both the bone and soft 
tissue structures (7).
- Bad odor (secondary to uremia) and metallic taste resul-
ting from the increased concentration of urea in saliva and 
its posterior transformation into ammonium (2,8,9,14). 
Glomerular function
% filtrate
Creatinine clearance Blood creatinine Clinical condition
100% 90-120 ml/min 0.5-1.3 mg/dl Normal
>50% >45-60 ml/min <1.3 mg/dl Renal compensation
25-50% 20-60 ml/min 1.3-2.5 mg/dl
Onset of clinically 
manifest chronic 
renal failure
10-25% 10-25 ml/min 2.5-10 mg/dl
Established clinical 
condition
<10% <10 ml/min >10 mg/dl Dialysis
Table 2. Equivalences between renal function tests and clinical expression.
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- Xerostomia (dry mouth), as a result of the restriction in 
fluid intake, the side effects of drugs (fundamentally an-
tihypertensive agents), possible salivary gland alteration, 
and oral breathing secondary to lung perfusion problems 
(2,8,9). 
- Paleness of  the mucosal membranes due to anemia 
(1,2,7,8).
- Uremic stomatitis, and uncommon clinical observation 
associated to uremia (1,2). As many as four types of ure-
mic stomatitis have been described: erythemo-pultaceous, 
ulcerative (1,2,8,15), hemorrhagic and hyperkeratotic. 
The lesions are very painful and most often appear on the 
ventral surface of the tongue and on the anterior mucosal 
surfaces (2). These lesions are resistant to treatment for as 
long as the blood urea levels remain high (15), and heal 
spontaneously within 2-3 weeks once the background renal 
disorder has been resolved (2,15). 
- Gingival bleeding (7,13), petechiae and ecchymosis (7), 
resulting from platelet dysfunction (13,14) and the effects 
of anticoagulants (14).
- Gingival inflammation. There is some controversy in the 
literature in relation to gingival inflammation in patients 
with CRF, since some studies report low incidences of 
gingivitis – explained in terms of immune suppression 
and uremia, which would inhibit gingival inflammatory 
response to plaque accumulation – while other studies 
report the opposite (16).
- Gingival hyperplasia secondary to drug treatment, which 
is one of the most widely documented oral manifestations 
in patients with renal failure (9). Such hyperplasia can 
be induced by cyclosporine, which is used in transplant 
patients, and/or calcium channel blockers (nifedipine, 
amlodipine, diltiazem, verapamil, etc.), in pre-dialyzed 
and dialyzed patients (7,9,16-18). The condition in turn 
is aggravated by the deficient oral hygiene (8,17,18). A 
number of studies suggest that replacing cyclosporine with 
tacrolimus may reduce the severity of gingival hyperplasia 
(7,9,16-18), and in any case thorough oral hygiene is requi-
red (7,17,18). The problem also can increase in incidence 
and severity when combining cyclosporine and nifedipine 
– this suggesting an additive effect (9,16,18). Hyperplasia 
mainly affects the labial surface of the interdental papilla, 
though greater extensions can be affected - including the 
gingival margins and lingual and palatal surfaces (9).
- Periodontal problems with important attachment loss, 
recesses and deep pockets (4,16).
- Enamel hypoplasia secondary to alterations in calcium 
and phosphorus metabolism (7), which can affect both 
the primary and permanent dentition (9). The severity 
of such hypoplasia is related to patient age at the time of 
presentation of these metabolic disorders, the duration of 
renal failure, and dialysis (16). 
- Severe erosions on the lingual surfaces of the teeth, due to 
frequent regurgitation and vomiting induced by uremia and 
medication, and nausea associated to dialysis (2,14). 
- Pulp obliteration, possibly related to the alterations in 
calcium and phosphorus metabolism (7).
- Delays or alterations in eruption (2,7).
- Changes in maxillary bone, secondary to renal osteo-
dystrophy (2,14). These changes comprise bone demine-
ralization with trabeculation and cortical loss (1,2,7,14), 
giant cell radiotransparencies or metastatic calcifications 
of the soft tissues (2). The patients are at increased risk 
of fracture during dental treatments such as extractions 
(1,2). Tooth mobility (2,9,14), malocclusion, crowding, 
pulp chamber calcifications (2) and temporomandibular 
joint problems are also observed (19).
- A diminished prevalence of caries has been observed 
and attributed to a protective effect on the part of urea, 
which inhibits bacterial growth and neutralizes bacterial 
plaque acids (1,4,14,19).
- Important tartar formation, induced by the increased 
levels of urea in saliva (19) and altered calcium and phos-
phorus metabolism (1).
- Infections. Candidiasis is common among both transplant 
patients and subjects on dialysis (1,9). Cytomegalovirus 
(CMV) infection is frequent in the first months after trans-
plantation (7), and prolonged immune suppression can 
increase patient vulnerability to human herpesvirus 8 (9).
- Mucosal lesions, particularly white lesions and/or ul-
cerations. Common observations are lichenoid lesions 
often (though not always) associated to medication (9), or 
oral hairy leukoplakia (OHL) secondary to drug-induced 
immune suppression (9,17). OHL is associated to the 
Epstein-Barr virus (EBV), and different studies suggest 
that primary infection occurs in the oropharynx, where 
the virus remains latent in the basal layers of the epithe-
lium until reactivation takes place as a result of immune 
depression – with the generation of tongue lesions (20).
- Malignization. An increased susceptibility to epithe-
lial dysplasia and carcinoma of  the lip attributable to 
the treatment following renal transplantation has been 
postulated (9,17). The increased risk of malignization in 
CRF probably reflects the effects of iatrogenic immune 
suppression, which increases mucosal susceptibility to 
virus-related tumors such as Kaposi’s sarcoma (9) or non-
Hodgkin lymphoma (9,17).
Treatment
a) Conservative management. Such treatment aims to 
prevent or correct the metabolic alterations and preserve 
the remaining renal functional capacity. The measures 
include a high carbohydrate and low protein diet (though 
consensus is lacking on this point) (6,9,21), body weight 
control (6), treatment with antihypertensive drugs, lipid-
lowering agents and vitamin D supplements (2,6,22), and 
correction of the anemia with erythropoietin (7).
b) Renal replacement therapy is considered when con-
servative management fails to be effective against the 
progression of renal deterioration, and comprises dialysis 
and renal transplantation (4,7).
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Dialysis is an artificial mechanism that clears blood of 
nitrogen waste and other toxic products of metabolism 
(1,2,19). Two modalities are currently used: peritoneal 
dialysis (PD) and hemodialysis (HD). In PD, access to the 
body is gained through a catheter placed in the abdominal 
wall and inserted in the peritoneum. The dialysate (sterile 
electrolyte solution) is introduced through the catheter, 
and the peritoneal membrane filters the blood waste pro-
ducts via an osmotic mechanism (2,7,19). In HD, blood 
filtration is carried out by a machine (dialyzer) (Figure 
1) equipped with a semipermeable membrane (Figure 2) 
allowing passage of the excess fluids and waste products 
(2,19). Most patients are subjected to dialysis three days a 
week. To this effect, an artificial permanent vascular access 
is placed in the form of a catheter or surgically performed 
arteriovenous fistula (2,9,23). During HD, the patients 
receive anticoagulation, generally in the form of heparin, 
to facilitate blood cycling through the dialyzer, and for 
ensuring permeability of the vascular access.
Renal transplantation is the treatment of choice in pa-
tients with irreversible renal failure (2,17). Immediately 
before transplantation, and after the surgical operation, 
immunosuppressive therapy must be provided to avoid 
acute rejection (7). This generally comprises combined 
treatment in the form of  corticosteroids, calcineurin 
inhibitors (cyclosporine, tacrolimus), and lymphocyte 
proliferation inhibitors (azathioprine, mycophenolate 
mofetil) (7,9). All transplant patients, with the exception 
of those receiving an organ from an identical twin, require 
life-long immunosuppressive therapy (4).
c) Prevention of infections. Infections are one of the most 
important causes of  morbidity and mortality in CRF. 
Vaccination is therefore potentially very useful in patients 
of this kind, though such treatment is underused, since 
no clear guidelines have been established, and vaccination 
response with the normal doses and regimens may be 
limited (24).
Prognosis
The life expectancy of patients on dialysis remains somber 
(approximately one-third that of the general population)
(23). The prognosis of individuals with diabetes mellitus 
and/or hypertension is poorer than that of patients with 
glomerulonephritis (7).
The most common causes of death among patients with 
ESRF are cardiovascular problems (about 50% of global 
mortality) (7,22,23), followed by infections (7,23) and 
malignization (7).
Dental management of renal failure patients
Patients with renal failure require special considerations 
in relation to dental treatment, not only because of the 
conditions inherent to the disease and its multiple oral 
manifestations, but also because of the side effects and 
characteristics of the treatments they receive.
1.- Consultation with the nephrologist provides infor-
mation on the state of the disease, the type of treatment, 
the best timing of dental management, or the medical 
complications that may arise (7). Any modification of 
the usual medication used by the patients or of  other 
aspects of their treatment must first be consulted with 
the nephrologist (1).
Fig. 2. Detail of the hemodialysis membrane.
Fig. 1. Hemodialysis machine in a hospital center.
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2.- Close cooperation between medical and dental pro-
fessionals is desirable in order to improve the oral and 
general health of the patient, based on the creation of a 
dental care program in the context of a multidiscipline 
approach to the disease (25).
3.- Prior to any invasive dental treatment, a complete blood 
count is to be obtained, together with coagulation tests, in 
view of the possible hematological alterations (1).
4.- It is essential to eliminate any infection in the oral 
cavity as soon as possible (2), with the consideration of 
antibiotic prophylaxis when bleeding and/or a risk of sep-
ticemia is expected (extractions, periodontal treatments, 
endodontics and periapical surgery, the placement of or-
thodontic braces, tartrectomy when bleeding is expected, 
implant surgery, and the reimplantation of  avulsioned 
teeth) (26,27).
5.- Blood pressure is to be monitored before and during 
treatment, with the administration of sedation to lessen 
anxiety (2).
6.- The metabolism and elimination of certain drugs are 
altered in situations of renal failure. In such cases dose 
adjustment or modification of the dosing frequency is 
needed (Table 3). The prescription of  aminoglycoside 
antibiotics and tetracyclines is to be avoided, because of 
their nephrotoxicity (1,2,9). Penicillins, clindamycin and 
cephalosporins can be administered at the usual doses, 
and are the antibiotics of  choice – though the dosing 
interval should be prolonged (2,9). As regards analgesics, 
paracetamol is the non-narcotic analgesic of choice in 
application to episodic pain. Aspirin possesses antiplatelet 
activity, and as such should be avoided in uremic patients 
(13). As regards the rest of nonsteroidal antiinflammatory 
drugs (indomethacin, ibuprofen, naproxen and sodium 
diclofenac), dose reduction or even avoidance is indicated 
in the more advanced stages of renal failure (1,2,9), since 
they inhibit prostaglandins and generate a hypertensive 
effect (1,9). Benzodiazepines can be prescribed without the 
need of dose adjustments, though excessive sedation may 
occur (1,2,13). The narcotic analgesics (codeine, morphine, 
fentanyl) are metabolized by the liver, and so usually do 
not require dose adjustment (1,2).
Dialyzed patients
Patients on peritoneal dialysis require no special mea-
sures as regards dental treatment, beyond those already 
commented above. We therefore will center our attention 
on hemodialysis.
Drug substance Elimination 1
Adjustment 
method 2
Adjustment in renal failure according to glomerular 
filtration rate (GFR)(ml/min)
> 50 10-50 < 10
ANTIMICROBIALS 
Amoxicillin
Erythromycin
Clindamycin
Metronidazole
Doxycycline
Ampicillin
Tetracycline
Aciclovir 
Ketoconazole 
R (H)
H
H
H (R)
H (R)
R (H)
R (H)
R
H
I
D
D
D
D
I
I
I
D
8
100
100
100
100
6
6-8
8
100
8-12
100
100
100
100
6-9
12-24
12-24
100
12-18
50-75
100
50
100
9-12
Avoid
48
100
ANALGESICS /
ANTIINFLAMMATORY 
Aspirin
Paracetamol
Ibuprofen
Diclofenac
Naproxen
H (R)
H (R)
H (R)
H
H
I
I
I
D
D
4
4
100
100
100
4-6
6-8
100
100
100
Avoid
8-12
Avoid
Avoid
Avoid
SEDATIVES 
Codeine
Diazepam 
Alprazolam
H (R)
H
H (R)
D
D
D
100
100
100
100
100
100
100
100
100
ANESTHETICS 
Lidocaine
Mepivacaine
H
H
D
D
100
100
100
100
100
100
OTHERS
Prednisone H D 100 100 100
Table 3. Dose adjustment of drugs used in dental practice, in patients with renal failure.
1. R = mainly renal elimination; H = liver metabolism. The letter in parentheses corresponds to the less important (but signifi-
cant) elimination route.
2. D = dose reduction expressed as % of the usual dose; I = prolongation of the dosing interval (in hours).
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- Due to the already mentioned reasons, dialyzed patients 
are at an increased risk of  bleeding. It is advisable to 
provide dental treatment on non-dialysis days, to ensure 
the absence of circulating heparin, which has a half-life 
of about four hours (9,14). In any case, prior to invasive 
procedures, it is important to request a complete blood 
count and coagulation tests (2), and to ensure that local he-
mostatic measures are available: mechanical compression, 
sutures (2,14), topical thrombin, microfibrilar collagen and 
oxidized regenerated cellulose. Desmopressin has been 
proposed for the control of severe bleeding in patients 
with renal failure, and conjugated estrogens can be used 
to achieve longer term hemostasia (13). Tranexamic acid 
in the form of a rinse (2) or administered via the oral route 
at a dose of 10-15 mg/kg body weight a day distributed in 
2-3 doses, may also prove useful (28).
- Although there is some controversy in the literature regar-
ding the need for antibiotic coverage to prevent bacterial 
endocarditis in dialyzed patients (2,26,27), endocarditis is 
effectively a potential complication in such patients. The 
recommended antibiotic regimen is 2 g of amoxicillin via 
the oral route one hour before the dental procedure. In 
the case of patients with allergy to penicillin, clindamycin 
is the drug of choice (600 mg via the oral route, one hour 
before the intervention).
- Dialyzed patients are subjected to numerous transfusions 
and blood exchanges, and this implies an increased risk of 
infection in the form of HIV, HBV, HCV and tuberculo-
sis. Periodic monitoring is required, with the adoption of 
measures to avoid both personal contagion on the part 
of the dental professional and cross-contamination in the 
dental clinic (2,13).
- Hemodialysis can affect the serum concentrations of di-
fferent drugs used by CRF patients, when such substances 
are administered before the dialysis session. Supplemen-
tary dosing after dialysis therefore may be needed (13).
Transplant patients
- It is important to conduct dental evaluation prior to 
renal transplantation, in order to eliminate the existing 
infectious foci. Teeth offering an uncertain prognosis are 
to be removed (1,7,9,14).
- The potential for oral infections after transplantation is 
very high, since these patients receive immunosuppressive 
therapy. Prophylactic antibiotic treatment is therefore 
indicated before invasive dental procedures are carried 
out (1).
- Prolonged corticosteroid therapy may make it necessary 
to administer a supplementary dose in situations of stress, 
such as when visiting the dentist, in order to avoid an 
adrenal crisis (1,7,9). The most recent guides recommend 
a dose of 25 mg of hydrocortisone via the intravenous 
route, before the intervention (9).
- In the first 6 months after transplantation, patients 
should avoid any elective dental treatment (1).
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